FibroBiologics Doses First Patients in Phase 1/2 DFU Trial, Ships Second GMP Run
FBLG•FibroBiologics dosed its first patients in a Phase 1/2 trial of CYWC628 for diabetic foot ulcers the week of June 1, 2026. The company released its second GMP manufacturing run for shipment to Australia in mid-June and has completed two batches of the third GMP run.
1. Initial Patient Dosing
FibroBiologics initiated dosing of its first patients in the Phase 1/2 clinical trial of CYWC628 for refractory diabetic foot ulcers during the week of June 1, 2026. The randomized study evaluates safety, tolerability and efficacy of low and high doses administered alongside standard of care.
2. Manufacturing Advancements
The company completed its second GMP manufacturing run of CYWC628 and scheduled shipment of drug product to Australia during the week of June 15, 2026. FibroBiologics has also finished the first two batches of a third GMP run to support escalating clinical supply needs.
3. Platform Scalability
Consecutive successful GMP runs underscore the reproducibility of FibroBiologics’ fibroblast manufacturing platform, ensuring product integrity and confidence in scaling capacity for ongoing and future clinical trials.
